Apixaban-Metabolism, Pharmacologic Properties and Drug Interactions

Current Drug Metabolism

Volumn 18, Issue 7, 2017, Pages 609-621

  Kubisz, Peter ^a   Stanciakova, Lucia ^a   Dobrotova, Miroslava ^a   Samos, Matej ^a   Mokan, Marian ^a   Stasko, Jan ^a  

^a University Hospital in Martin   (Slovakia)

Author keywords

Anti Xa activity; Apixaban; Bleeding; Drug interactions; Elimination; Metabolism; New oral anticoagulants; Pharmacology

Indexed keywords

ABIRATERONE; APIXABAN; BEXAROTENE; BICALUTAMIDE; CARBAMAZEPINE; CRIZOTINIB; CYCLOSPORINE; DEXAMETHASONE; DILTIAZEM; ENZALUTAMIDE; IMATINIB; ITRACONAZOLE; KETOCONAZOLE; LEVETIRACETAM; NAPROXEN; OXCARBAZEPINE; PACLITAXEL; PHENOBARBITAL; PHENYTOIN; POSACONAZOLE; PREDNISONE; RIFAMPICIN; RITONAVIR; TOPIRAMATE; VALPROIC ACID; VEMURAFENIB; VIRAL PROTEINASE INHIBITOR; VORICONAZOLE; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ABSORPTION; ADVERSE EVENT; BLOOD LEVEL; BODY WEIGHT; BRAIN CIRCULATION; BREAST MILK; CONTRAINDICATION; DATA BASE; DRUG INTERACTION; FETUS CIRCULATION; FOOD DRUG INTERACTION; HEMOSTASIS; HUMAN; KIDNEY DISEASE; LIVER FAILURE; METABOLISM; PHARMACOLOGY; REVIEW; SCIENTIFIC LITERATURE; THROMBOSIS; ANIMAL; DRUG CONTRAINDICATION;

ANIMALS; CONTRAINDICATIONS, DRUG; DRUG INTERACTIONS; FACTOR XA INHIBITORS; HUMANS; PYRAZOLES; PYRIDONES;

EID: 85048119827     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200218666170424151551     Document Type: Review

References (88)

1. Mandernach, M.W.; Beyth, R.J.; Rajasekhar, A. Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review. Ther. Clin. Risk. Manag., 2015, 11, 1273-1282.
2. Mekaj, Y.H.; Mekaj, A.Y., Duci, S.B., Miftari, E.I. New oral anti-coagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther. Clin. Risk Manag., 2015, 11, 967-977.
3. Bauer, K.A. Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa. J. Thromb. Haemost., 2011, 9 Suppl 1, 12-19.
4. Bonar, R.; Favaloro, E.J.; Mohammed, S.; Ahuja, M.; Pasalic, L.; Sioufi, J.; Marsden, K. The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: A comprehensive assessment using in vitro and ex vivo samples. Pathology, 2016, 48(1), 60-71.
5. SlideShare: Coagulants. LinkedIn Corporation: 2013; (http://www.slideshare.net/shrinathraman/coagulants) (Accessed June 8, 2016).
6. Miller, C.S.; Grandi, S.M.; Shimony, A.; Filion, K.B.; Eisenberg, M.J. Meta-analysis of efficacy and safety of new oral anticoagu-lants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am. J. Cardiol., 2012, 110(3), 453-460.
7. Pubchem-Open Chemistry Database: Apixaban-Compound Summary for CID 10182969. National Center for Biotechnology Information, U.S. National Library of Medicine: Rockville Pike, 2016. (https://pubchem.ncbi.nlm.nih.gov/compound/Apixaban#section=N ames-and-Identifiers) (Accessed June 25, 2016).
8. Song, Y.; Chang, M.; Suzuki, A.; Frost, R.J.; Kelly, A.; LaCreta, F.; Frost, C. Evaluation of crushed tablet for oral administration and the effect of food on apixaban pharmacokinetics in healthy adults. Clin. Ther., 2016, S0149-2918(16) 30310-30311.
9. Frost, C.; Wang, J.; Nepal, S.; Schuster, A.; Barrett, Y.C.; Mosqueda-Garcia, R.; Reeves, R.A.; LaCreta, F. Apixaban, an oral, direct factor Xa inhibitor: Single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br. J. Clin. Pharmacol., 2013,75(2), 476-487.
10. Dempfle, C.E. Direct oral anticoagulants-pharmacology, drug interactions, and side effects. Semin Hematol., 2014, 51(2), 89-97.
11. Gong, I.Y.; Kim, R.B. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, ri-varoxaban, and apixaban. Can. J. Cardiol., 2013, 29(7 Suppl), S24-S33.
12. He, K., Luettgen, J.M.; Zhang, D.; He, B.; Grace, J.E. Jr.; Xin, B.; Pinto, D.J.; Wong, P.C.; Knabb, R.M.; Lam, P.Y.; Wexler, R.R.; Grossman, S.J. Preclinical pharmacokinetics and pharmacodynam-ics of apixaban, a potent and selective factor Xa inhibitor. Eur. J. Drug Metab. Pharmacokinet., 2011, 36(3), 129-139.
13. Frost, C.E.; Song, Y.; Shenker, A.; Wang, J.; Barrett, Y.C.; Schus-ter, A.; Harris, S.I.; LaCreta, F. Effects of age and sex on the sin-gle-dose pharmacokinetics and pharmacodynamics of apixaban. Clin. Pharmacokinet., 2015, 54(6), 651-662.
14. Frost, C.; Wang, J.; Nepal, S.; Schuster, A.; Barrett, Y.C.; Mosqueda-Garcia, R.; Reeves, R.A.; LaCreta, F. Apixaban, an oral, direct factor Xa inhibitor: Single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br. J. Clin. Pharmacol., 2013, 75(2), 476-487.
15. Heidbuchel, H.; Verhamme, P.; Alings, M.; Antz, M.; Diener, H. C.; Hacke, W.; Oldgren, J.; Sinnaeve, P.; Camm, A.J.; Kirchhof, P. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonistanticoagulants in patients with non-valvular atrial fibrillation. Europace., 2015, 17(10), 1467-1507.
16. Wong, P.C.; Pinto, D.J.; Zhang, D. Preclinical discovery of apixa-ban, a direct and orally bioavailable factor Xa inhibitor. J. Thromb. Thrombolysis., 2011, 31(4), 478-492.
17. Wang, X.; Tirucherai, G.; Marbury, T.C.; Wang, J.; Chang, M.; Zhang, D.; Song, Y.; Pursley, J.; Boyd, R.A.; Frost, C. Pharma-cokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J. Clin. Pharmacol., 2016, 56(5), 628-636.
18. Palladino, M.; Thomson, L.; Swift, B.; Merli, G.J. Implementing the new oral anticoagulants into the hospital formulary. Am. J. He-matol., 2012, 87 Suppl 1, S127-S!32.
19. Zalpour, A.; Oo T.H. Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: Current evidence. Drug Des. Devel. Ther., 2014, 8, 2181-2191.
20. Raghavan, N.; Frost, C.E.; Yu, Z.; He, K.; Zhang, H.; Humphreys, W. G.; Pinto, D.; Chen, S.; Bonacorsi, S.; Wong, P.C.; Zhang, D. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab. Dispos., 2009, 37(1), 74-81.
21. Liakoni, E.; Rätz Bravo, A. E.; Krähenbühl, S. Hepatotoxicity of New Oral Anticoagulants (NOACs). Drug Saf., 2015, 38(8), 711-720.
22. Caldeira, D.; Barra, M.; Santos, A. T.; de Abreu, D.; Pinto, F.J.; Ferreira, J.J.; Costa, J. Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. Heart., 2014, 100(7), 550-556.
23. Anastasia, E.J.; Rosenstein, R.S.; Bergsman, J.A.; Parra, D. Use of apixaban after development of suspected rivaroxaban-induced hepatic steatosis; a case report. Blood Coagul. Fibrinolysis., 2015, 26(6), 699-702.
24. Cordeanu, M.; Lambert, A.; Gaertner, S.; Nouri, S.; Mirea, C.; Alt-Tebacher, M.; Stephan, D. Apixaban-induced hepatotoxicity. Int. J. Cardiol., 2016, 204, 4-5.
25. Potze W.; Adelmeijer, J.; Lisman, T. Decreased in vitro anticoagu-lant potency of rivaroxaban and apixaban in plasma from patients with cirrhosis. Hepatology, 2015, 61(4), 1435-1436.
26. Graff, J.; Harder, S. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic im-pairment. Clin. Pharmacokinet., 2013, 52(4), 243-254.
27. Hart, R.G.; Eikelboom, J.W.; Ingram, A.J.; Herzog, C.A. Antico-agulants in atrial fibrillation patients with chronic kidney disease. Nat. Rev. Nephrol., 2012, 8(10), 569-578.
28. Connolly, S.J.; Eikelboom, J.; Joyner, C.; Diener, H.C.; Hart, R.; Golitsyn, S.; Flaker, G.; Avezum, A.; Hohnloser, S.H.; Diaz, R.; Talajic, M.; Zhu, J.; Pais, P.; Budaj, A.; Parkhomenko, A.; Jansky, P.; Commerford, P.; Tan, R.S.; Sim, K.H.; Lewis, B.S.; Van Mieghem, W.; Lip, G.Y.; Kim, J.H.; Lanas-Zanetti, F.; Gonzalez-Hermosillo, A.; Dans, A.L.; Munawar, M.; O'Donnell, M.; Law-rence, J.; Lewis, G.; Afzal, R.; Yusuf, S. AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fib-rillation. N. Engl. J. Med., 2011, 364(9), 806-817.
29. Turagam, M.K.; Velagapudi, P.; Flaker, G.C. Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants. Clin. Interv. Aging., 2015, 10, 1431-1444.
30. Eikelboom, J.W.; Connolly, S.J.; Gao, P.; Paolasso, E.; De Caterina, R.; Husted, S.; O'Donnell, M.; Yusuf, S.; Hart, R.G. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J. Stroke Cerebrovasc. Dis., 2012, 21(6), 429-435.
31. Steffel, J.; Hindricks, G. Apixaban in renal insufficiency: success-ful navigation between the Scylla and Charybdis. Eur. Heart J., 2012, 33(22), 2766-2768.
32. Granger, C.B.; Alexander, J.H.; McMurray, J.J.; Lopes, R.D.; Hylek, E.M.; Hanna, M.; Al-Khalidi, H.R.; Ansell, J.; Atar, D.; Avezum, A.; Bahit, M.C.; Diaz, R.; Easton, J.D.; Ezekowitz, J.A.; Flaker, G.; Garcia, D.; Geraldes, M.; Gersh, B.J.; Golitsyn, S.; Goto, S.; Hermosillo, A.G.; Hohnloser, S.H.; Horowitz, J.; Mohan, P.; Jansky, P.; Lewis, B.S.; Lopez-Sendon, J.L.; Pais, P.; Park-homenko, A.; Verheugt, F.W.; Zhu, J.; Wallentin, L. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med., 2011, 365(11), 981-992.
33. Hohnloser, S.H.; Hijazi, Z.; Thomas, L.; Alexander, J.H.; Amerena, J.; Hanna, M.; Keltai, M.; Lanas, F.; Lopes, R.D.; Lopez-Sendon, J.; Granger, C.B.; Wallentin, L. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation:insights from the ARISTOTLE trial. Eur. Heart J., 2012, 33(22), 2821-2830.
34. Poulsen, B.K.; Grove, E.L.; Husted, S.E. New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. Drugs, 2012, 72(13), 1739-1753.
35. Chang, M.; Yu, Z.; Shenker, A.; Wang, J.; Pursley, J.; Byon, W.; Boyd, R. A.; LaCreta, F.; Frost, C. E. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J. Clin. Pharmacol., 2016, 56(5), 637-645.
36. Manzano-Fernández, S.; Andreu-Cayuelas, J.M.; Marín, F.; Ore-nes-Piñero, E.; Gallego, P.; Valdés, M.; Vicente, V.; Lip, G.Y.; Roldán, V. Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation. Rev. Esp. Cardiol (Engl Ed)., 2015, 68(6), 497-504.
37. Pathak, R.; Pandit, A.; Karmacharya, P.; Aryal, M.R.; Ghimire, S.; Poudel, D.R.; Shamoun, F.E. Meta-analysis on risk of bleeding with apixaban in patients with renal impairment. Am. J. Cardiol., 2015, 115(3), 323-327.
38. Sardar, P.; Chatterjee, S.; Herzog, E.; Nairooz, R.; Mukherjee, D.; Halperin, J. L. Novel oral anticoagulants in patients with renal in-sufficiency: a meta-analysis of randomized trials. Can. J. Cardiol., 2014, 30(8), 888-897.
39. Hijazi, Z.; Oldgren, J.; Lindbäck, J.; Alexander, J.H.; Connolly, S.J.; Eikelboom, J.W.; Ezekowitz, M.D.; Held, C.; Hylek, E.M.; Lopes, R.D.; Siegbahn, A.; Yusuf, S.; Granger, C.B.; Wallentin, L.; ARISTOTLE and RE-LY Investigators. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet., 2016, 387(10035), 2302-2311.
40. O'Brien, E.C.; Simon, D.N.; Thomas, L.E.; Hylek, E.M.; Gersh, B.J.; Ansell, J.E.; Kowey, PR.; Mahaffey, K. W.; Chang, P.; Fon-arow, G.C.; Pencina, M.J.; Piccini, J.P.; Peterson, E.D. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur. Heart J., 2015, 36(46), 3258-3264.
41. National Center for Biotechnology Information-Bookshelf: Stroke Prevention in Atrial Fibrillation [Internet].-Abbreviations. National Center for Biotechnology Information, U.S. National Library of Medicine: Rockville Pike, 2013; (http://www.ncbi.nlm.nih.gov/books/NBK159052/) (Accessed June 26, 2016).
42. Delgado-García, G.; Monreal-Robles, R.; Gallegos-Arguijo, D.; Marfil-Rivera, J. Apixaban as therapeutic option in nephropathy patients with heparin-induced thrombocytopenia (HIT). Gac. Med. Mex., 2015, 151(6), 798-801.
43. January, C.T.; Wann, L.S.; Alpert, J.S.; Calkins, H.; Cigarroa, J.E.; Cleveland, J.C. Jr.; Conti, J.B.; Ellinor, P.T.; Ezekowitz, M.D.; Field, M.E.; Murray, K.T.; Sacco, R.L.; Stevenson, W.G.; Tchou, P.J.; Tracy, C.M.; Yancy, C.W.; American College of Cardiol-ogy/American Heart Association Task Force on Practice Guide-lines., 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J. Am. Coll. Cardiol., 2014, 64(21), e1-e76.
44. Kearon C.; Akl, E.A.; Ornelas, J.; Blaivas, A.; Jimenez, D.; Bou-nameaux, H.; Huisman, M.; King, C.S.; Morris, T. A.; Sood, N.; Stevens, S.M.; Vintch, J.R.; Wells, P.; Woller, S.C.; Moores, L. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest., 2016, 149(2), 315-352.
45. Hart, R.G.; Eikelboom, J.W.; Brimble, K.S.; McMurtry, M.S.; Ingram, A.J. Stroke prevention in atrial fibrillation patients with chronic kidney disease. Can. J. Cardiol., 2013, 29(7 Suppl), S71-78.
46. Zhang, D.; He, K.; Herbst, J.J.; Kolb, J.; Shou, W.; Wang, L.; Balimane, P.V.; Han, Y.H.; Gan, J.; Frost, C.E.; Humphreys, W.G. Characterization of efflux transporters involved in distribution and disposition of apixaban. Drug Metab. Dispos., 2013, 41(4), 827-835.
47. Bapat, P.; Pinto, L.S.; Lubetsky, A.; Aleksa, K.; Berger, H.; Koren, G.; Ito, S. Examining the transplacental passage of apixaban using the dually perfused human placenta. J Thromb Haemost., 2016, doi: 10.1111/jth.13353. [Epub ahead of print].
48. Upreti, V. V.; Wang, J.; Barrett, Y. C.; Byon, W.; Boyd, R. A.; Pursley, J.; LaCreta, F.P.; Frost, C.E. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability ofapixaban in healthy subjects. Br. J. Clin. Pharmacol., 2013, 76(6), 908-916.
49. Ward, C.; Conner, G.; Donnan, G.; Gallus, A.; McRae, S. Practical management of patients on apixaban: A consensus guide. Thromb. J., 2013, 11(1), 27.
50. Wang, L.; Zhang, D.; Raghavan, N.; Yao, M.; Ma, L.; Frost, C.E.; Maxwell, B. D.; Chen, S.Y.; He, K.; Goosen, T.C.; Humphreys, W.G.; Grossman, S.J. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 pheno-typing, inhibition, and induction studies. Drug. Metab. Dispos., 2010, 38(3), 448-458.
51. Frost, C.E.; Byon, W.; Song, Y.; Wang, J.; Schuster, A.E.; Boyd, R.A.; Zhang, D.; Yu, Z.; Dias, C.; Shenker, A.; LaCreta, F. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixa-ban, an oral direct factor Xa inhibitor. Br. J. Clin. Pharmacol., 2015, 79(5), 838-846.
52. Hellwig, T.; Gulseth, M. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation? Ann. Pharmacother., 2013, 47(11), 1478-1487.
53. Dushenkov, A.; Kalabalik, J.; Carbone, A.; Jungsuwadee, P. Drug interactions with aprepitant or fosaprepitant: Review of literature and implications for clinical practice. J. Oncol. Pharm. Pract., 2016, pii: 1078155216631408. [Epub ahead of print]
54. Frost, C.; Shenker, A.; Gandhi, M.D.; Pursley, J.; Barrett, Y.C.; Wang, J.; Zhang, D.; Byon, W.; Boyd, R.A.; LaCreta, F. Evaluation of the effect of naproxen on the pharmacokinetics and pharma-codynamics of apixaban. Br. J. Clin. Pharmacol., 2014, 78(4), 877-885.
55. Walenga, J.M.; Adiguzel, C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int. J. Clin. Pract., 2010, 64(7), 956-967.
56. Vakkalagadda, B.; Frost, C.; Byon, W.; Boyd, R.A.; Wang, J.; Zhang, D.; Yu, Z.; Dias, C.; Shenker, A.; LaCreta, F. Effect of Ri-fampin on the Pharmacokinetics of Apixaban, an Oral Direct In-hibitor of Factor Xa. Am. J. Cardiovasc. Drugs, 2016, 16(2), 119-127.
57. Peacock, W.F.; Rafique, Z.; Singer, A.J. Direct-Acting Oral Anti-coagulants: Practical Considerations for Emergency Medicine Phy-sicians. Emerg. Med. Int., 2016, 2016, 1781684.
58. Stöllberger, C.; Finsterer, J. Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs. Epilepsy Res., 2016, 126, 98-101.
59. Egan, G.; Hughes, C.A.; Ackman, M.L. Drug interactions between antiplatelet or novel oral anticoagulant medications and antiretrovi-ral medications. Ann. Pharmacother., 2014, 48(6), 734-40.
60. Short, N.J.; Connors, J.M. New oral anticoagulants and the cancer patient. Oncologist., 2014, 19(1), 82-93.
61. Hess, C.N.; James, S.; Lopes, R.D.; Wojdyla, D.M.; Neely, M.L.; Liaw, D.; Hagstrom, E.; Bhatt, D.L.; Husted, S.; Goodman, S.G.; Lewis, B.S.; Verheugt, F.W.; De Caterina, R.; Ogawa, H.; Wallentin, L.; Alexander, J.H. Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights From the APPRAISE-2 Trial. J. Am. Coll. Cardiol., 2015, 66(7), 777-787.
62. Rubboli, A.; Agewall, S.; Huber, K.; Lip, G.Y. New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopi-dogrel? A viewpoint. Int. J. Cardiol., 2015, 196, 133-138.
63. van Nieuwenhuizen, K.M.; van der Worp, H.B.; Algra, A.; Kap-pelle, L.J.; Rinkel, G.J.; van Gelder, I.C.; Schutgens, R.E.; Klijn, C.J.; APACHE-AF Investigators. Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial. Trials., 2015, 16, 393.
64. Stöllberger, C.; Finsterer, J. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban. Herz., 2015, 40 Suppl 2, 140-145.
65. Pujadas-Mestres, L.; Escolar, G.; Arellano-Rodrigo, E.; Galán, A. M. Apixaban in the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. Drugs Today (Barc)., 2013, 49(7), 425-436.
66. U. S. Food and Drug Administration-News & Events: FDA approves Eliquis to reduce the risk of stroke, blood clots in patients with non-valvular atrial fibrillation. FDA: Silver Spring, 2012; (http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333634.htm) (Accessed June 28, 2016).
67. MEDPAGETODAY®: FDA OKs Apixaban for DVT Prevention. MedPage Today®, 2014; (http://www.medpagetoday.com/Cardio-logy/VenousThrombosis/44776) (Accessed June 28, 2016).
68. Pfizer: U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy. Pfizer: East 42nd Street, 2014; (http://www. pfizer.com/news/press-release/press-release-detail/u_s_fda_app-roves_eliquis_apixaban_for_the_treatment_of_deep_vein_thrombo sis_dvt_and_pulmonary_embolism_pe_and_for_the_reduction_in_t he_risk_of_recurrent_dvt_and_pe_following_initial_therapy) (Ac-cessed June 28, 2016).
69. Hanna, M.S.; Mohan, P.; Knabb, R.; Gupta, E.; Frost, C.; Law-rence, J. H. Development of apixaban: A novel anticoagulant for prevention of stroke in patients with atrial fibrillation. Ann. N. Y. Acad. Sci., 2014, 1329, 93-106.
70. TrialResults-center: Table summary of clinical trials for apixaban. TrialResults-center database, 2016; (http://www.trialresult-scenter.org/DR-apixaban%20clinical%20trials.htm) (Accessed June 28, 2016).
71. Rybak, I.; Ehle, M.; Buckley, L.; Fanikos, J. Efficacy and Safety of Novel Anticoagulants Compared with Established Agents. Ther. Adv. Hematol., 2011, 2(3), 175-195.
72. Cada, D.J.; Levien, T.L.; Baker, D.E. Apixaban. Hosp. Pharm., 2013, 48(6), 494-509.
73. Imberti, D.; Gallerani, M.; Manfredini, R. Therapeutic potential of apixaban in the prevention of venous thromboembolism in patients undergoing total knee replacement surgery. J. Thromb. Thromboly-sis., 2012, 34(2), 208-213.
74. Lassen, M.R.; Davidson, B.L.; Gallus, A.; Pineo, G.; Ansell, J.; Deitchman, D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J. Thromb. Haemost., 2007, 5(12), 2368-2375.
75. Lassen, M.R.; Raskob, G.E.; Gallus, A.; Pineo, G.; Chen, D.; Hor-nick, P.; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet., 2010, 375(9717), 807-15.
76. Lassen, M.R.; Raskob, G.E.; Gallus, A.; Pineo, G.; Chen, D.; Port-man, R.J. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N. Engl. J. Med., 2009, 361(6), 594-604.
77. Lassen, M.R.; Gallus, A.; Raskob, G.E.; Pineo, G.; Chen, D.; Ra-mirez, L.M.; ADVANCE-3 Investigators. Apixaban versus enoxa-parin for thromboprophylaxis after hip replacement. N. Engl. J. Med., 2010, 363(26), 2487-2498.
78. Goldhaber, S.Z.; Leizorovicz, A.; Kakkar, A.K.; Haas, S.K.; Merli, G.; Knabb, R.M.; Weitz, J.I.; ADOPT Trial Investigators. Apixa-ban versus enoxaparin for thromboprophylaxis in medically ill pa-tients. N. Engl. J. Med., 2011, 365(23), 2167-2177.
79. Botticelli Investigators, Writing Committe; Buller, H.; Deitchman, D.; Prins, M.; Segers, A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J. Thromb. Haemost., 2008, 6(8), 1313-1318.
80. Agnelli, G.; Buller, H.R.; Cohen, A.; Curto, M.; Gallus, A.S.; John-son, M.; Masiukiewicz, U.; Pak, R.; Thompson, J.; Raskob, G.E.; Weitz, J.I.; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N. Engl. J. Med., 2013, 369(9), 799-808.
81. Agnelli, G.; Buller, H.R.; Cohen, A.; Curto, M.; Gallus, A.S.; John-son, M.; Porcari, A.; Raskob, G.E.; Weitz, J.I.; PLIFY-EXT Inves-tigators. Apixaban for extended treatment of venous thromboem-bolism. N. Engl. J. Med., 2013, 368(8), 699-708.
82. Hylek, E.M.; Held, C.; Alexander, J.H.; Lopes, R.D.; De Caterina, R.; Wojdyla, D.M.; Huber, K.; Jansky, P.; Steg, P.G.; Hanna, M.; Thomas, L.; Wallentin, L.; Granger, C.B. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Charac-teristics, and Clinical Outcomes. J. Am. Coll. Cardiol., 2014, 63(20), 2141-2147.
83. Skaistis, J.; Tagami, T. Risk of Fatal Bleeding in Episodes of Major Bleeding with New Oral Anticoagulants and Vitamin KAntago-nists: A Systematic Review and Meta-Analysis. PLoS One., 2015, 10(9), e0137444.
84. Bahit, M.C.; Lopes, R.D.; Wojdyla, D.M.; Held, C.; Hanna, M.; Vinereanu, D.; Hylek, E.M.; Verheugt, F.; Goto, S.; Alexander, J.H.; Wallentin, L.; Granger, C.B. Non-major bleeding with apixa-ban versus warfarin in patients with atrial fibrillation. Heart., 2016, pii: heartjnl-2016-309901. doi: 10.1136/heartjnl-2016-309901. [Epub ahead of print]
85. APPRAISE Steering Committee and Investigators; Alexander, J. H.; Becker, R. C.; Bhatt, D. L.; Cools, F.; Crea, F.; Dellborg, M.; Fox, K. A.; Goodman, S. G.; Harrington, R. A.; Huber, K.; Husted, S.; Lewis, B. S.; Lopez-Sendon, J.; Mohan, P.; Montalescot, G.; Ruda, M.; Ruzyllo, W.; Verheugt, F.; Wallentin, L. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with anti-platelet therapy after acute coronary syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (AP-PRAISE) trial. Circulation., 2009, 119(22), 2877-2885.
86. Alexander, J. H.; Lopes, R. D.; James, S.; Kilaru, R.; He, Y.; Mohan, P.; Bhatt, D. L.; Goodman, S.; Verheugt, F. W.; Flather, M.; Huber, K.; Liaw, D.; Husted, S. E.; Lopez-Sendon, J.; De Caterina, R.; Jansky, P.; Darius, H.; Vinereanu, D.; Cornel, J. H.; Cools, F.; Atar, D.; Leiva-Pons, J. L.; Keltai, M.; Ogawa, H.; Pais, P.; Parkhomenko, A.; Ruzyllo, W.; Diaz, R.; White, H.; Ruda, M.; Geraldes, M.; Lawrence, J.; Harrington, R. A.; Wallentin, L.; AP-PRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. N. Engl. J. Med., 2011, 365(8), 699-708.
87. Drugs.com: Eliquis. Drugs.com, 2016; (https://www.drugs.com/pro/eliquis.html#ID_9d76b0fe-861e-4956-b53d-0e7696084ee2) (Accessed June 29, 2016).
88. Chen, C.; Yang, F. Q.; Zhang, Q.; Wang, F. Q.; Hu, Y. J.; Xia, Z. N. Natural Products for Antithrombosis. Evid. Based Complement. Alternat. Med., 2015, 2015, 876426.